Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

ves of women with advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data

    Herceptin

    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)

    Xeloda

    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.

    Avastin

    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014  RedRick Technologies, ... solutions and reading room environment guidance, has helped ... musculoskeletal radiology reading room, which may also serve ... at Penn Medicine. "In line ... American College of Radiology,s Imaging 3.0 ™ ...
(Date:11/21/2014)... Depomed, Inc. (NASDAQ: DEPO ) today announced ... Annual Healthcare Conference in New York City ... scheduled for 8:00 am EST (5:00 am PST) on Tuesday December ... be accessed via the Investor Relations page of the Depomed website ... archived for 30 days on the company,s website. ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... BRISTOL, Tenn., May 22, 2007,/PRNewswire-FirstCall/ -- Palatin ... that data from Study 16 and,Study 17 ... evaluating,bremelanotide in men with erectile dysfunction (ED) ... (AUA) Annual,Meeting (AUA 2007) held in Anaheim, ...
... Abuse-Related Effects For OROS(r),Methylphenidate , Two New ... , SAN DIEGO, CA, May 22, 2007 ... for parents and physicians who prescribe,medications to ... on Tuesday at the 160th Annual Meeting ...
Cached Medicine Technology:Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 2Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 3Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 4Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 5Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 6Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide 7New Data Focuses on Abuse of Stimulant Medication 2New Data Focuses on Abuse of Stimulant Medication 3New Data Focuses on Abuse of Stimulant Medication 4New Data Focuses on Abuse of Stimulant Medication 5
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 BambooFlooringChina.com ... the company has proudly released its new collection of ... discounted rates, up to 29% off. , According ... and sturdy tree-like grass, making it a highly renewable resource. ... products have a mixing color which comes from natural bamboo ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
Breaking Medicine News(10 mins):Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... Karen Ignagni, President and CEO of America,s Health Insurance ... the President,s budget:"Today,s budget submission sends a signal to ... prioritizing health care. We applaud the President for ... resources to put our nation on a path towards ...
... SEO Online PR & Marketing Consultancy, is pleased to announce the ... successful Industry Directory, offering free listings to relevant specialist industries. ... ... B2B, SEO Online PR & Marketing Consultancy , is pleased ...
... N.C., Feb. 26 Arbor Pharmaceuticals, a specialty,pharmaceutical ... the company has launched XYLAREX - a first-in-class ... media (middle ear,infections). XYLAREX is a novel ... the number of ear infections children experience. ...
... Feb. 26 A lawsuit was filed today by ... who contracted salmonella poisoning,after eating at a Blueberry Hill ... child was hospitalized for three days as a result ... Cook County Department of Health,after the Communicable Disease Unit ...
... groups nationwide to receive National Autism Conference DVD ... Association (NAA) today announced its receipt of a ... (CWF) to disseminate DVD sets of complete presentations ... organizations throughout the United States, U.S. territories, and ...
... to continuing multi-pronged effort to raise awarenessWASHINGTON, Feb. 26 ... for a Drug-Free America offers some promising news regarding ... According to the 20th annual Partnership Attitude Tracking Survey ... about drugs and alcohol, an increased number of teens ...
Cached Medicine News:Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2Health News:National Autism Association Announces American Legion Child Welfare Grant for Autism Outreach 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 2Health News:New Partnership for a Drug-Free America 20th Annual Study Shows Progress in Teens Recognizing Dangers of OTC Cough Medicine Abuse 3
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... primary known naturally-occurring stimulant of red blood ... human EPO is 18.2 kDa. Due to ... an estimated molecular mass of ~30.5 kDa. ... unique structure, the EPO receptor bears some ...
... Alpha Fetoprotein (AFP) is a 68 kDa protein, ... the fetal liver and yolk sac [1]. ... weeks gestation, and production rates reach 19-26 g/min ... and estimates of total fetal AFP continue to ...
Medicine Products: